Navigation Links
Affymax Reports Phase 2 Clinical Dose Ranging Results of,Once-Per-Month Hematide for the Treatment of Anemia

PALO ALTO, Calif.--(BUSINESS WIRE)--Jun 25, 2007 - Affymax, Inc. (Nasdaq:AFFY) today announced that additional Phase 2 clinical trial results for Hematide(TM) were presented at the European Renal Association-EDTA Congress being held in Barcelona, Spain by Iain C. Macdougall, M.D., a Hematide investigator from Kings College, London. Dr. Macdougall's poster included data in previously-treated dialysis patients and treatment naive, non-dialysis patients which demonstrated that mean hemoglobin (Hgb) levels could be maintained and corrected, respectively, with once monthly Hematide.

Specifically, the data showed that in non-dialysis patients an initial range of doses from .025 mg/kg to .075 mg/kg of Hematide, in conjunction with dose adjustments, is adequate to increase Hgb in anemic patients with renal failure when administered monthly. In addition, intravenous and subcutaneous dosing appeared to result in a similar Hgb increase.

"These data support further investigation of the versatility and flexibility of once-per-month Hematide in terms of starting doses and route of administration," said Robert Naso, Ph.D., executive vice president of Research and Development at Affymax. "These results demonstrate that a narrow target range of hemoglobin levels can be reached with different initial Hematide doses. We are pleased to have such thorough evaluation of the product as we prepare for pivotal Phase 3 clinical trials."

At the time of the presentation, the data generated to date were from two multi-center, open-label studies that have enrolled a total of 304 patients. Safety data were based on the entire patient population, while pharmacodynamic data were based on 179 patients who had mostly completed six months of treatment at European and U.S. clinical sites. Of those, 89 treatment-naive CKD patients who were not on dialysis in the correction study were treated with Hematide once every four weeks. The me
'"/>




Page: 1 2 3

Related medicine technology :

1. Affymax Announces Phase 2 Clinical Trial Results of Once-Per-Month Hematide for the Treatment of Anemia in Patients with Early- and End-Stage Chronic Kidney Disease
2. Affymax Announces Results From Phase 2 Clinical Trial of Hematide for the Treatment of Anemia in Dialysis Patients
3. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
4. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
5. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
6. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
7. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
8. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
9. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
10. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
11. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
Post Your Comments:
(Date:5/16/2008)...ektar,s Technology Enables First-Ever PEGylation o...ated Therapeutic Activity, SAN CARLOS, Calif., Ma... (Nasdaq: NKTR ) announced initial results today ...tecan. The data shows significant,anti-tumor activ...study,also demonstrates that Nektar,s small molecu...
(Date:5/16/2008)...- ANX-530 Demonstrates Statistically Significant R...ety Observations, - Abstract to be published in 20... Clinical Oncology, SAN DIEGO, M...ticals,Inc. (Amex: ANX ) announced today that, i...ANX-530 demonstrated a statistically significant r...
(Date:5/15/2008)... SAN FRANCISCO, May 15 /- ...that data from an ongoing Phase 1-2 clinical,trial...0, will be presented,in an oral presentation at th...) Annual Meeting in Chicago., Session title: Ne...ancer Session date and time: Monday, June 2 at 11...
(Date:5/15/2008)... MELBOURNE, Australia, May 15 /PRNewswire-FirstCa...that the abstract for its upcoming oral,presentati...rican Society,of Clinical Oncology (ASCO) will be ...://www.asco.org ) from 9pm on Thursday 15 May (US ...valuation of CYT997, a novel,cytotoxic and vascula...
Breaking Medicine Technology:Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings 2Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings 3Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings 4Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings 5ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study 2ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study 3ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study 4ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study 5Medivation Announces Presentation of MDV3100 Clinical Data in Patients With Castration-Resistant Prostate Cancer at 44th American Society of Clinical Oncology Annual Meeting 2Medivation Announces Presentation of MDV3100 Clinical Data in Patients With Castration-Resistant Prostate Cancer at 44th American Society of Clinical Oncology Annual Meeting 3Advanced Bionics Deploys CEVA TeakLite 28TM 29 DSP Core to Enhance Its Harmony 28TM 29 HiResolution 28R 29 Bionic Ear System 637 1Advanced Bionics Deploys CEVA TeakLite 28TM 29 DSP Core to Enhance Its Harmony 28TM 29 HiResolution 28R 29 Bionic Ear System 637 2Advanced Bionics Deploys CEVA TeakLite 28TM 29 DSP Core to Enhance Its Harmony 28TM 29 HiResolution 28R 29 Bionic Ear System 637 3Safer Simpler Better 26 Cost Effective Cosmetic Surgery Anesthesia 1450 1Safer Simpler Better 26 Cost Effective Cosmetic Surgery Anesthesia 1450 2Safer Simpler Better 26 Cost Effective Cosmetic Surgery Anesthesia 1450 3Sisko Foundation Gears Up to Pick Up The Pace Against Breast Cancer 1445 1Sisko Foundation Gears Up to Pick Up The Pace Against Breast Cancer 1445 2Large Blinded Clinical Study Achieves High Accuracy for the Diagnosis of Melanoma Using In Vivo Confocal Microscopy 292 1Large Blinded Clinical Study Achieves High Accuracy for the Diagnosis of Melanoma Using In Vivo Confocal Microscopy 292 2Large Blinded Clinical Study Achieves High Accuracy for the Diagnosis of Melanoma Using In Vivo Confocal Microscopy 292 3
...buting Editor , ,Celiac disease (CD) is an au...ne that is triggered in genetically susceptible pe...ains wheat, rye, barley, and possibly oats. The co...f both a T-cell and B-cell immune response, leadin...ypt hyperplasia, and is self-perpetuating with con...
...uting Editor ,Since the first system was inven... clinical medicine and patient care. During the 19...available, and blood gases were considered "the mo...tients," according to a www.bloodgas.org article b... analysis system., ,Blood gas tests determine ...
Other Medicine Technology:Non-Invasive Diagnostic Tests for Celiac Disease 2Non-Invasive Diagnostic Tests for Celiac Disease 3Blood Gas Analysis: The Pros and Cons of Point-Of-Care Testing 2Blood Gas Analysis: The Pros and Cons of Point-Of-Care Testing 3Blood Gas Analysis: The Pros and Cons of Point-Of-Care Testing 4
(Date:5/16/2008)...ffices of Howard G. Smith,announces a June 9, 2008...ecurities class action lawsuit filed on behalf of ...e common stock of Inverness Medical,Innovations, I... IMA ) in the,Company,s secondary public offering .... The shareholder lawsuit is pending in the United...
(Date:5/16/2008)...s want agency to act, not wait years , ,...umer drug ads on television should include a toll-...port adverse side effects, U.S. health experts sug...hat advises the U.S. Food and Drug Administration....A for print ads. At Friday,s meeting, the panel di...
(Date:5/16/2008)...HINGTON, May 16 /PRNewswire-USNewswire/ -- More th...s in the Greater Portland, Oregon and,Vancouver, W...ract as,Teamsters., "The Teamsters are pleased th...act that gives them job protection and a secure re... Jim Hoffa., The workers, both full-time and part...
(Date:5/16/2008)...fit from calcitriol, an oral form , , FR...vitamin D may cut the risk of death for people wit...ut one quarter, a new study suggests. , During...se being treated with calcitriol, an oral form of ...th lowered by 26 percent when compared with those ...
Breaking Medicine News(10 mins):Health News:Law Offices of Howard G. Smith Announces 24 Days Remaining to Move to Be a Lead Plaintiff in the Shareholder Lawsuit Against Inverness Medical Innovations, Inc. 2Health News:FDA Panel Considers Toll-Free Number for TV Drug Ads 2Health News:FDA Panel Considers Toll-Free Number for TV Drug Ads 3Health News:Vitamin D Use Linked to Lower Mortality in Kidney Patients 2
...the British Government would be conducting a separ...nsultant radiologist in Ireland. // These clinical... scanner and have necessitated the recall of close...ir breast cancer examinations. The enquiry team w...
...ries is in the threat of ban on their export of se...food from Asian countries had the banned chemical ...el that the Canadian Food Inspection Agency should...d test all batches of imported seafood coming into...
... was brought home in a very uncomfortable manner w...e of the greatest footballers' died in London yest...after his own liver failed in the aftermath of his...case. Millions of people the world over, mostly ma...
...-1) is required for both cartilage and bone growth...d by the pituitary gland.// Deficiency of IGF-1 re...tabolic abnormalities including insulin resistance...IGF-1 drugs helps in production of IGF-1 in childr...
Other Medicine News:
...aboratories is a national reference laboratory and...rch and development. ARUP offers an extensive test...n clinical and anatomic pathology. Owned by the Un...de more than half of the nation's university teach...
...aboratories is a national reference laboratory and...rch and development. ARUP offers an extensive test...n clinical and anatomic pathology. Owned by the Un...de more than half of the nation's university teach...
...aboratories is a national reference laboratory and...rch and development. ARUP offers an extensive test...n clinical and anatomic pathology. Owned by the Un...de more than half of the nation's university teach...
...aboratories is a national reference laboratory and...rch and development. ARUP offers an extensive test...n clinical and anatomic pathology. Owned by the Un...de more than half of the nation's university teach...
Medicine Products: